OxySure (OXYS) Announces First Australian Approval
FRISCO, TX -- (Marketwired) -- 06/24/14 -- OxySure Systems, Inc. (OTCQB: OXYS) ("OxySure (OXYS)," or the "Company"), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology is pleased to announce that the first of two approvals was received from the Therapeutic Goods Administration ("TGA") in Australia. The TGA approved the OxySure Model 615 cartridge for commercialization in Australia as a medical device under Class IIa with effect from June 2, 2014.
The TGA is the regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia. It is a Division of the Australian Department of Health established under the Therapeutic Goods Act of 1989. The TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard and that access to therapeutic advances is in a timely manner.
Speaking from a roadshow in New York, Julian Ross, CEO of OxySure stated: "This approval brings us one step closer to our Australian launch plans. We continue to work with our Australian partner, Aero Healthcare on these launch plans as we wait for the second and final approval from the TGA."
About OxySure Systems, Inc.
OxySure Systems, Inc. (OTCQB: OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.
Investor Contact:Stonegate Securities, Inc.214-987-4121 / firstname.lastname@example.org Media Contact:email@example.com
Source: OxySure Systems, Inc.